Noninvasive risk stratification in postinfarction patients with severe left ventricular dysfunction and methodology of the MADIT II noninvasive electrocardiology substudy.
Sudden cardiac death occurs as a result of a complex interplay of changes in myocardial substrate, imbalance of autonomic regulation of the heart, and myocardial vulnerability. Noninvasive electrocardiology serves as a comprehensive tool for investigating factors representing mechanistic pathways leading to cardiac events. Heart rate variability, nonlinear dynamics of heart rate, and heart rate turbulence provide insight into autonomic control of the heart. Prognostic value of these parameters in postinfarction patients is well established for predicting cardiac death, but there is less evidence for their association with sudden death or arrhythmic events. Electrical manifestation of changes in myocardial substrate include QRS and QTc prolongation, presence of conduction disturbances, presence of late potentials, abnormalities of repolarization morphology, and presence of nonsinus rhythm, namely atrial fibrillation. Electrocardiogram (ECG) measures reflecting myocardial vulnerability to arrhythmias include frequent ventricular premature beats, T wave alternans, or QT variability. Prognostic significance of these parameters is documented in studies focused mostly on them as individual markers of risk. The noninvasive electrocardiology substudy of the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) allows for simultaneous analysis of several of the above ECG markers of risk and will provide insight about relative contribution of mechanistic pathways leading to cardiac death in postinfarction patients with severe left ventricular dysfunction. Combination of a standard 12-lead ECG and 10-minute high-resolution Holter recordings serves to evaluate the prognostic significance of noninvasive electrocardiology parameters for mortality in patients randomized to conventional treatment and for arrhythmic events in patients randomized to implantable cardioverter defibrillator therapy.
Zareba
Wojciech
W
Heart Research Follow-up Program, Cardiology Unit, University of Rochester, NY 14618, USA. heartwz@heart.rochester.edu
Moss
Arthur J
AJ
D001281:Atrial Fibrillation / Q000503:physiopathology; D016757:Death, Sudden, Cardiac; D004562:Electrocardiography; D015716:Electrocardiography, Ambulatory; D006339:Heart Rate; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000150:complications*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020414:Risk Sharing, Financial; D018487:Ventricular Dysfunction, Left / Q000209:etiology / Q000503:physiopathology*